Earnings summaries and quarterly performance for Viking Therapeutics.
Executive leadership at Viking Therapeutics.
Board of directors at Viking Therapeutics.
Research analysts who have asked questions during Viking Therapeutics earnings calls.
Annabel Samimy
Stifel Financial Corp.
8 questions for VKTX
Also covers: ALT, APLS, CARA +14 more
Hardik Parikh
JPMorgan Chase & Co.
8 questions for VKTX
Also covers: PCRX, RPRX
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
8 questions for VKTX
Also covers: AFMD, ALDX, ARCT +14 more
Ryan Deschner
Raymond James Financial
7 questions for VKTX
Also covers: APLS, ARDX, ARSP +7 more
Jay Olson
Oppenheimer & Co. Inc.
6 questions for VKTX
Also covers: ACAD, AMGN, BIIB +23 more
JL
Joon Lee
Truist Securities
6 questions for VKTX
Also covers: ADVM, ALKS, AXSM +15 more
Justin Zelin
BTIG, LLC
5 questions for VKTX
Also covers: BCAB, CASI, GLMD +9 more
Mayank Mamtani
B. Riley Securities
5 questions for VKTX
Also covers: AGEN, ALT, ARWR +18 more
RS
Roger Song
Jefferies
5 questions for VKTX
Also covers: AADI, AKBA, ALT +14 more
Biren Amin
Piper Sandler Companies
4 questions for VKTX
Also covers: ALLO, APLS, BBIO +5 more
Rohit Bhasin
Morgan Stanley
4 questions for VKTX
Also covers: GUTS, MIRM
TS
Thomas Smith
Leerink Partners
4 questions for VKTX
Also covers: ACRS, ARGX, CLDX +7 more
AH
Andy Hsieh
William Blair & Company
3 questions for VKTX
Also covers: ALT, BYSI, CRDF +8 more
MU
Michael Ulz
Morgan Stanley
3 questions for VKTX
Also covers: ALNY, ARWR, FATE +8 more
Steve Seedhouse
Cantor Fitzgerald
3 questions for VKTX
Also covers: BCRX, BOLD, HROW +1 more
AH
Andy Hsieh
William Blair
2 questions for VKTX
Also covers: LNTH, TLX
AR
Asim Rana
Truist Securities
2 questions for VKTX
Also covers: AXSM, CORT, CPRX +2 more
GF
George Farmer
Scotiabank
2 questions for VKTX
Also covers: ABSI, ADAP, INMB +7 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for VKTX
Also covers: ACRS, CRVS, CTMX +12 more
KP
Kushal Patel
Leerink
2 questions for VKTX
Timur Ivannikov
Raymond James
2 questions for VKTX
Also covers: APLS, GLMD, IFRX +1 more
TH
Tsan-Yu Hsieh
William Blair & Company
2 questions for VKTX
Also covers: AVIR, CRDF, EXEL +6 more
WW
William Wood
B. Riley Securities
2 questions for VKTX
Also covers: ALT, GUTS, IMUX +6 more
AR
Alexandra Ramsey
William Blair & Company, L.L.C.
1 question for VKTX
Also covers: NKTR
BA
Barron Amon
Piper Sandler
1 question for VKTX
FG
Fiona Gia
Jefferies
1 question for VKTX
JM
Jeet Mukherjee
Leerink Partners
1 question for VKTX
Also covers: ARVN, BCAB, KURA +4 more
NC
Nat Charoensook
Leerink Partners
1 question for VKTX
Also covers: ARGX, IMUX
SS
Steven Seedhouse
Raymond James
1 question for VKTX
Also covers: APLS, BCRX, EDIT +2 more
Recent press releases and 8-K filings for VKTX.
Viking Therapeutics Reports Q4 and Full Year 2025 Financial Results, Advances VK2735 Programs
VKTX
Earnings
New Projects/Investments
Hiring
- Viking Therapeutics reported a net loss of $157.7 million ($1.38 per share) for Q4 2025 and $358.5 million ($3.19 per share) for the full year, primarily driven by increased research and development expenses.
- The company ended 2025 with $706 million in cash, cash equivalents, and short-term investments, confirming sufficient funding to reach top-line data for its ongoing maintenance trial, Phase 3 subcutaneous trials, and planned oral Phase 3 trials.
- Enrollment for the VANQUISH-1 Phase 3 study of subcutaneous VK2735 was completed ahead of schedule in Q4 2025, and the company plans to initiate Phase 3 development for oral VK2735 in Q3 2026.
- Viking expects results from its VK2735 maintenance dosing study in Q3 2026 and appointed Neil Aubuchon as Chief Commercial Officer in January 2026 to lead commercial strategy.
Feb 11, 2026, 9:30 PM
Viking Therapeutics Reports Q4 and Full Year 2025 Financial Results and Provides Pipeline Updates
VKTX
Earnings
New Projects/Investments
Management Change
- Viking Therapeutics reported a net loss of $157.7 million or $1.38 per share for Q4 2025 and a net loss of $358.5 million or $3.19 per share for the full year 2025. Research and development expenses significantly increased to $153.5 million in Q4 2025 and $345 million for the full year 2025, primarily due to increased clinical trial activity.
- The company made significant progress with its lead obesity program, VK2735, completing enrollment ahead of schedule for the VANQUISH-1 Phase 3 study (subcutaneous formulation) in Q4 2025 and nearing completion for VANQUISH-2.
- For the oral VK2735 program, positive top-line results from the Phase 2 VENTURE oral dosing study were announced in Q3 2025, showing statistically significant weight reductions. Following an end-of-Phase 2 meeting with the FDA, Viking plans to initiate Phase 3 development for oral VK2735 in Q3 2026.
- As of December 31, 2025, Viking held $706 million in cash, cash equivalents, and short-term investments. The company confirmed it has sufficient cash to fund operations through major catalysts, including the upcoming maintenance trial, data from subcutaneous Phase 3 trials, and oral Phase 3 trials, to top-line data.
- Viking appointed Neil Aubuchon as Chief Commercial Officer to oversee the development and execution of its commercial strategy.
Feb 11, 2026, 9:30 PM
Viking Therapeutics Reports Q4 and Full Year 2025 Financial Results, Advances VK2735 Programs to Phase III
VKTX
Earnings
New Projects/Investments
Hiring
- Viking Therapeutics reported a net loss of $157.7 million or $1.38 per share for the fourth quarter of 2025 and a net loss of $358.5 million or $3.19 per share for the full year 2025, primarily driven by increased research and development expenses.
- The company maintained a strong balance sheet with $706 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
- For its lead obesity program, VK2735, Viking initiated the Phase III VANQUISH clinical program for the subcutaneous formulation, completing enrollment for VANQUISH-1 ahead of schedule and nearing completion for VANQUISH-2.
- The oral VK2735 formulation achieved positive top-line results from its Phase II VENTURE-Oral Dosing study and is slated to advance into Phase III development in the third quarter of 2026.
- To support potential commercialization, Viking signed a comprehensive manufacturing and supply agreement with CordenPharma for VK2735 and appointed Neil Aubuchon as Chief Commercial Officer.
Feb 11, 2026, 9:30 PM
Viking Therapeutics Reports Q4 and Full-Year 2025 Financial Results and Provides Pipeline Update
VKTX
Earnings
New Projects/Investments
Guidance Update
- Viking Therapeutics reported a net loss of $157.7 million, or $1.38 per share, for the fourth quarter ended December 31, 2025, and a net loss of $358.5 million, or $3.19 per share, for the full year ended December 31, 2025, with a cash position of $706 million as of December 31, 2025.
- The company plans to advance oral VK2735 into Phase 3 development for obesity in 3Q26.
- Enrollment for the Phase 3 VANQUISH-1 trial for subcutaneous VK2735 in obesity is complete, and VANQUISH-2 is nearing full enrollment.
- Data from the fully enrolled VK2735 maintenance dosing study is expected in 3Q26.
- An Investigational New Drug (IND) application for a novel amylin agonist is planned for filing in 1Q26.
Feb 11, 2026, 9:16 PM
Viking Therapeutics Reports Q4 and Full-Year 2025 Financial Results and Provides Pipeline Update
VKTX
Earnings
New Projects/Investments
Guidance Update
- For the fourth quarter ended December 31, 2025, Viking Therapeutics reported a net loss of $157.7 million, or $1.38 per share, and for the full year 2025, a net loss of $358.5 million, or $3.19 per share.
- The company ended December 31, 2025, with a strong cash position of $706 million in cash, cash equivalents, and short-term investments.
- Viking plans to advance oral VK2735 into Phase 3 development for obesity in 3Q26.
- Enrollment for the Phase 3 VANQUISH-1 study for subcutaneous VK2735 is complete, and VANQUISH-2 is nearing full enrollment.
- The VK2735 maintenance dosing study is fully enrolled, with data expected in 3Q26, and an Investigational New Drug (IND) filing for a novel amylin agonist is planned for 1Q26.
Feb 11, 2026, 9:06 PM
Viking Therapeutics Provides Clinical Pipeline and Trial Updates
VKTX
New Projects/Investments
Product Launch
- Viking Therapeutics' VK2735 (injectable), a GLP-1/GIP dual agonist for obesity, is in its VANQUISH Phase 3 program, with VANQUISH 1 enrollment complete and VANQUISH 2 enrollment expected to complete in 1Q26.
- The VK2735 Oral formulation for obesity successfully achieved its primary endpoint in the VENTURE Oral Phase 2 study, demonstrating up to 14.7% mean weight loss after 13 weeks of treatment.
- The oral VK2735 showed promising tolerability, with the majority of GI-related adverse events being mild to moderate and occurring early in treatment.
- Other pipeline programs include VK2809 for MASH, which reported successful Phase 2b data in 2Q24, and VK0214 for X-ALD, which reported successful Phase 1b data in 4Q24.
Jan 14, 2026, 12:00 PM
Viking Therapeutics Provides Updates on VK2735 Clinical Programs and Financial Position
VKTX
New Projects/Investments
Guidance Update
- Viking Therapeutics is advancing its lead compound, VK2735, a dual GLP-1 and GIP receptor agonist, with Vanquish I Phase III trial enrollment completed and Vanquish II Phase III trial enrollment on track for Q1 2026. Data from these trials are anticipated in the 2027 timeframe.
- The oral formulation of VK2735 completed a Phase II study, demonstrating up to 12% body weight reduction after 13 weeks, with data submission for the European Conference on Obesity in Q2 2026. A sub-Q to oral maintenance study has completed enrollment, with data expected around mid-year or Q3 2026.
- The company maintains a strong financial position, reporting over $700 million in cash as of the end of the third quarter.
- Viking Therapeutics plans to file an Investigational New Drug (IND) for its amylin program in the first quarter of 2026.
- The company's VK2809 program for MASH is currently open for licensing.
Jan 12, 2026, 10:15 PM
Viking Therapeutics Provides Pipeline Update at J.P. Morgan Healthcare Conference
VKTX
New Projects/Investments
Product Launch
- Viking Therapeutics' CEO presented updates on its metabolic disease programs, highlighting VK2735, a dual GLP-1/GIP agonist, with its injectable formulation in Phase III (VANQUISH program), where VANQUISH I enrollment is complete and VANQUISH II is on track for Q1 2026 completion, with data expected in 2027.
- The oral formulation of VK2735 completed its Phase II study, demonstrating up to 12% body weight reduction after 13 weeks, with data submission planned for Q2 2026 and an end-of-Phase II FDA meeting held in December 2025. The company views the oral form as best suited for maintenance therapy.
- The company maintains a strong balance sheet with over $700 million in cash as of the end of Q3 2025.
- Viking Therapeutics plans to file an Investigational New Drug (IND) application for its amylin program in Q1 2026.
Jan 12, 2026, 10:15 PM
Viking Therapeutics Provides Update on VK2735 Programs and Financials
VKTX
New Projects/Investments
Product Launch
Guidance Update
- Viking Therapeutics' lead compound, VK2735, a dual GLP-1 and GIP agonist, is currently in a Phase III program (Vanquish) for obesity and obesity with type 2 diabetes.
- An oral formulation of VK2735 completed a Phase II study in late summer 2025, with data submission planned for the European Conference on Obesity in Q2 2026.
- A Phase I maintenance study for VK2735, exploring subcutaneous to oral transition, has fully enrolled, with data expected around mid-year or Q3 2026.
- The company reported a strong balance sheet with over $700 million in cash as of the end of Q3 2025.
- Phase III readouts for the Vanquish trials are anticipated in the 2027 timeframe.
Jan 12, 2026, 10:15 PM
Viking Therapeutics Announces Publication of Phase 2 VENTURE Trial Results for VK2735
VKTX
New Projects/Investments
- Viking Therapeutics announced the publication of positive results from its Phase 2 VENTURE clinical trial of VK2735 in the journal Obesity.
- The trial demonstrated statistically significant mean body weight reductions of up to 14.7% from baseline after 13 weeks in participants receiving VK2735, with an encouraging safety and tolerability profile.
- VK2735, a dual GLP-1/GIP receptor agonist, is currently being evaluated in the VANQUISH Phase 3 registrational program for obesity.
- The VANQUISH-1 study has completed enrollment of approximately 4,650 adults, and the VANQUISH-2 study is expected to complete enrollment in the first quarter of 2026.
Jan 12, 2026, 12:00 PM
Quarterly earnings call transcripts for Viking Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more